US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
21-Jun-16
$586 million

Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.